Sofinnova Partners has completed the fundraising for its second crossover investment fund, securing €725 million to support life sciences companies, with a particular focus on European biotechnology and medical technology businesses approaching commercialisation.
Fund Targets Clinical-Stage European Companies
The European venture capital firm said Sofinnova Crossover II will primarily invest in clinical-stage biopharmaceutical and medical technology companies seeking funding to progress towards commercialisation.
Although Europe will remain the fund’s main investment market, the strategy also allows for selective investments in leading companies in the United States and other international markets.
The fund is supported by the European Tech Champions Initiative (ETCI), a fund-of-funds programme managed by the European Investment Fund (EIF).
Previous Fund Delivered Major Investment Milestones
The new fund follows the firm’s first crossover investment vehicle, Sofinnova Crossover I, which supported several companies that subsequently achieved significant corporate and financial milestones.
Among its portfolio companies were LimFlow, which was acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; and Amolyt Pharma, which was acquired by AstraZeneca.
Another company backed by the first fund, Abivax, went on to secure a listing on the Nasdaq stock exchange.
Three Companies Already Backed by Crossover II
Sofinnova Crossover II has already made investments in three companies: Hemab Therapeutics, CellCentric and Neurent Medical.
The fund expects to build a portfolio of approximately 15 companies over its investment period, maintaining its primary focus on European businesses while pursuing selected opportunities in other markets.
Investment Strategy Led by Five Partners
The fund’s investment strategy is being overseen by five Sofinnova Partners: Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat and David Evans.
Their mandate will centre on identifying and financing companies with the potential to advance clinical-stage innovations towards commercial markets.
Sofinnova Partners Manages More Than €4 Billion
Founded in 1972, Sofinnova Partners is a life sciences venture capital firm with offices in Paris, London and Milan.
The firm manages more than €4 billion in assets and invests across the life sciences sector.
Its activities include supporting companies developing biopharmaceutical and medical technology innovations.